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We have also shown in a recent twin study that the rate of
progression of knee OA has a strong heritable basis.
Reports of significant associations for candidate genes for com-
mon forms of OA of the knee and hip now include over 50 genes
– and over a dozen have now been replicated independently.
These include VDR, ERG, CILP, Col2A1, AACT, BMP-2, FRZB,
ADAM12, IL-1, IL-1-RA, ASPN, LRCH1, matrillin3, COMP, and
OPG. Linkage studies using families and affected sib pairs have
to date shown a number of significant replicated loci, especially
areas on chromosome 2q and Chromosome 19.
OA is best studied genetically by dividing the phenotype into
its constituent parts and by studying intermediate phenotypes,
which may operate independently or together in clusters deter-
mined by pleiotropic genes. For example Cartilage loss at the
fingers or knee medial compartment or serum COMP or bone
turnover marker levels have all been shown to be heritable.
In conclusion, OA is a strongly genetic disease, which is likely
to be a complex polygenic disorder that may differ genetically by
gender site and race. We now have more than a dozen replicated
genes and are close to being able to use these clinically for both
diagnosis and clinically to predict progression and prognosis.
Understanding how the individual genes influence the many
intermediate processes is likely to be a fruitful avenue to provide
insight into disease pathways and potential new drug targets.
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TISSUE ENGINEERING BASED ON MUSCLE-DERIVED
STEM CELLS: POTENTIAL APPLICATIONS FOR TISSUE
REGENERATION
Johnny Huard
Summary: Members of my laboratory have isolated various pop-
ulations of myogenic cells from the postnatal skeletal muscle of
normal mice on the basis of the cells’ adhesion characteristics,
proliferation behavior, and myogenic and stem cell marker ex-
pression profiles. Although most of these cell populations have
displayed characteristics similar to those of satellite cells, we
also have identified a unique population of muscle-derived stem
cells (MDSCs). MDSCs exhibit long-term proliferation and high
self-renewal rates and can differentiate toward various lineages,
both in vitro and in vivo. The transplantation of MDSCs, in
contrast to that of other myogenic cells, has improved the ef-
ficiency of dystrophic muscle regeneration and the delivery of
dystrophin to dystrophic muscle. The ability of MDSCs to pro-
liferate in vivo for an extended period of time, combined with
their capacity to exhibit self-renewal, multipotent differentiation,
and transplantation. Recent studies performed by members of
my laboratory have shown that transplantation of female MDSCs
(F-FMSCs) rather than male MDSCs (M-MDSCs) significantly
improves skeletal muscle regeneration despite the similar myo-
genic and stem cell marker expression by both cell types. I will
explain the increased muscle regeneration efficiency exhibited
by F-MDSCs. My presentation will also address the influence of
environmental cues within dystrophic or injured skeletal muscle
on the differentiation of MDSCs into fibrotic cells. I will discuss
potential strategies by which to prevent scar tissue formation
within injured muscle by blocking TGF-β1 activity. I then will dis-
cuss the use of MDSCs in gene therapy and tissue engineering
applications designed to improve bone and articular cartilage
healing through the genetic modification of MDSCs to express
osteogenic proteins (BMP2 and -4) and the angiogenic factor
VEGF. I will also outline in my presentation new results obtained
with human muscle derived stem cells, which we believe will
open new avenues by which researchers could use muscle stem
cell-based gene therapy and tissue engineering to improve tissue
regeneration.
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NEW THERAPEUTIC STRATEGIES AND AGENTS WITH
STRUCTURE MODIFYING POTENTIAL IN
OSTEOARTHRITIS
Jean-Pierre Pelletier
Over the last decade, there have been several interesting ad-
vances in the treatment of osteoarthritis (OA). A clearer under-
standing of the pathophysiology of this disease has facilitated
the development of new approaches for treatments aimed at
specifically and effectively retarding the progress of the disease.
Several new classes of molecules that inhibit one or more OA
pathophysiological processes are under evaluation for their po-
tential to alter the degenerative process.
Osteoarthritis can be described primarily as the degradation and
loss of articular cartilage accompanied by subchondral bone
remodeling, osteophyte formation, and synovial membrane in-
flammation. The most attractive recent findings are the data
pointing to an association between inflammation and disease
appearance and progression. There is significant interest in new
agents that have the potential to reduce or stop the progression
of structural changes observed in OA. Such agents offer great
promise and are likely to lead to very significant changes in
therapeutic approaches in the near future.
The use of NSAIDs or COX-2 selective inhibitors has shown that
PGE2 inhibition alone has not proven to delay the natural history
of progressive OA. Other lipid mediators, including leukotrienes
(LT), could play a major role in the development and persistence
of the inflammatory process, and it is now clear that PG and LT
have complementary effects. Recent studies have also revealed
that LTB4 potently stimulated the release of pro-inflammatory
cytokines, such as IL-1β and TNF-α in human OA synovial
membrane. Thus, the failure of NSAIDs to impact OA progression
in these tissues could be due to the fact that inhibiting only the
COX pathways leads to a shunt to LT production. Based on this
concept, it is hypothesized that blocking production of both LT
and PGE2 could have a synergistic effect in achieving an optimal
or a wider spectrum of anti-inflammatory activity.
Pro-inflammatory cytokines are likely responsible for some of
the signs and symptoms as well as structural changes present
in OA patients. There exists a number of ways by which the
production or activity of cytokines could be reduced. These will
be reviewed in brief. The action of cytokines can be reduced at
the cell membrane level by decreasing the membrane receptor
level or by the use of receptor antagonists or soluble receptors.
Blocking the intracellular signaling pathways is another way to
reduce the action of the cytokine.
The natural IL-1 receptor antagonist (IL-1Ra) is capable of re-
ducing several cartilage catabolic processes that are IL-1β de-
pendent. In vivo studies in animal models have demonstrated
that the intra-articular injection of IL-1Ra could block the action
of IL-1β and reduce disease progression. Data from early phase
clinical trials in knee OA patients have also shown interesting
symptomatic effects of IL-1Ra.
Another interesting target for controlling the activity of the IL-1
system is the IL-1 converting enzyme (ICE)/caspase-1, an en-
zyme which is responsible for the conversion of the proform of IL-
1β into its active (mature) form. Usage of ICE inhibitor also repre-
sents another interesting potential target for the treatment of OA.
The role of proteases in the degradation of the extracellular
matrix of cartilage in OA has been well documented, and met-
alloproteases (MMPs) are believed to play a major role in this
process. Inhibition of the synthesis/activity of these enzymes as
a treatment for OA has been the focus of intensive research.
To date, the most promising strategy is still the use of chemical
molecules that can block the activity of MMPs. A number of
these compounds that have a broad range of MMP activities
have already been tested in clinical trials. From these trials, we
